2016
DOI: 10.1038/ajg.2016.92
|View full text |Cite
|
Sign up to set email alerts
|

Cronkhite Canada Syndrome: Significant Response to Infliximab and a Possible Clue to Pathogenesis

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4

Citation Types

0
21
0

Year Published

2017
2017
2024
2024

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 24 publications
(22 citation statements)
references
References 5 publications
0
21
0
Order By: Relevance
“…37 The underlying molecular biology mechanism of CCS has been less thoroughly investigated, with only two WES studies that provide possible clue. 6,7 In this study, we performed RNA-Seq analysis on the gastric polyps and identified INHBA, one of the top 15 upregulated genes in the tissue. In addition, the protein-protein interaction network analysis suggested that INHBA was at the center of the interaction network and might play an important role in CCS.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…37 The underlying molecular biology mechanism of CCS has been less thoroughly investigated, with only two WES studies that provide possible clue. 6,7 In this study, we performed RNA-Seq analysis on the gastric polyps and identified INHBA, one of the top 15 upregulated genes in the tissue. In addition, the protein-protein interaction network analysis suggested that INHBA was at the center of the interaction network and might play an important role in CCS.…”
Section: Discussionmentioning
confidence: 99%
“…One whole exome sequencing (WES) study identified a rare protein kinase DNA-activated catalytic subunit DNA variant that might be related to CCS pathogenesis. 6 Another WES study identified mutations in mucin-3A (MUC3A) that may provide insight into CCS pathogenesis. 7 Therefore, novel techniques are needed to investigate the mechanism for promising therapeutic targets and improve patient prognosis.…”
mentioning
confidence: 99%
“…The problem with hormone therapy is recurrence during dosage reduction, which occurs in nearly 40% of patients. [ 3 , 10 ] Azathioprine, cyclosporin A, and anti-TNF agents can be used in relapsed patients, [ 11 13 ] but these are mostly single cases or reported in small samples, and there is a lack of control studies on large samples.…”
Section: Discussionmentioning
confidence: 99%
“…Combination therapy with azathioprine and cyclosporine has been used in steroid-resistant cases [13]. There are three recent case reports using anti-tumor necrosis factor antibody therapy with success [14, 15]. Overall, reports of steroid-sparing therapies in CCS are sparse.…”
Section: Discussionmentioning
confidence: 99%